Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-29
2005-03-29
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S214000, C546S225000, C548S200000, C548S517000, C548S537000, C514S330000, C514S365000, C514S422000, C514S423000
Reexamination Certificate
active
06872735
ABSTRACT:
The invention relates to novel compounds having formula (I)wherein Cy, X, Y, L and R1-6are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
REFERENCES:
patent: 4665077 (1987-05-01), Stringfellow et al.
patent: 0 849 256 (1998-06-01), None
patent: WO 9708133 (1997-03-01), None
patent: WO 9804247 (1998-02-01), None
patent: WO 9949856 (1999-10-01), None
patent: WO 0039081 (2000-07-01), None
Morris, P., “Therapeutic Strategies in Immunosuppression after Renal Transplantation”J. Pediatrics111:1004-1007 (1987).
U.S. Appl. No. 09/191,927, Burdick, D. et al, filed Nov. 13, 1998.
Burdick Daniel J.
Gadek Thomas R.
Marsters James C.
Oare David
Reynolds Mark E.
Aulakh Charanjit S.
Evans David W
Genentech Inc.
LandOfFree
LFA-1 antagonist compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with LFA-1 antagonist compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LFA-1 antagonist compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380042